Effectiveness and Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Early Outcomes from Poland’s First Psychiatric Drug Program B.147
European Psychiatry June 1, 2026 O. Płaza, R. Madejek, M. M. Dutsch-Wicherek et al.
Introduction Treatment-resistant depression (TRD), which affects about 30% of patients with major depressive disorder, emerges when patients do not respond adequately to at least two antidepressant trials of proper dose and duration. The EMA approved esketamine nasal spray, the first registered psychedelic medication, in 2019 for TRD treatment. In July 2023, Poland launched B.147, the country’s...